Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations
Cancers · 03.05.2026 · 18 (9) · 1471
DOI: 10.3390/cancers18091471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 03.05.2026. Verfasst von Dor Shpitzer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv 6423906, Israel. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The survival of patients experiencing transformation of follicular lymphoma (tFL) is generally inferior to that of their non-transformed FL counterparts. While rituximab (R) has been shown to reduce transformation rates, data on Obinutuzumab (O), a third generation anti-CD20 monoclonal antibody, are limited.
Methods
This retrospective study analyzed risk factors for tFL and evaluated outcomes following transformation in 1145 consecutive patients with FL (2010–2023).
Results
Over a median follow-up of 70 months, 9% (n = 103) of FL patients developed tFL, with a median time of 36 months from FL diagnosis to transformation. In multivariate analysis, O-based, compared to R-based regimens and maintenance therapy (compared to no maintenance), were independently associated with reduced risk of histologic transformation (HR 0.40, 95% CI 0.19–0.90, p = 0.026 and HR 0.42, 95% CI 0.23–0.77, p = 0.005, respectively). Transformed FL was associated with shorter overall survival (OS) from FL diagnosis compared to non-transformed FL (median not reached, p < 0.001), while prior exposure to anti-FL chemoimmunotherapy predicted shorter OS following transformation (median 34.6 months vs. not reached, p = 0.001). Multivariate analysis confirmed prior exposure to anti-FL therapy (HR 5.27, p < 0.001), male sex (HR 2.36, p = 0.014), and age over 65 (HR 2.54, p = 0.019) to be associated with shorter OS among patients with tFL.
Conclusions
These findings, although requiring further validation, suggest that O-based regimens may reduce the risk of transformation and support prior studies demonstrating adverse survival outcomes in previously treated tFL patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv 6423906, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
- Kahn Sagol Maccabi Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv 6812509, Israel.
- Follicular Lymphoma Foundation, London NW3 6HJ, UK.
ORCID-Profile: Dor Shpitzer, Tamir Shragai, Roy Vitkon
Zitieren
APA
Shpitzer, D., Perry, C., Shragai, T., Melamed, G., Smith, M. R., Vitkon, R., Alapi, H., & Avivi, I. (2026). Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations. Cancers, 18(9), 1471. https://doi.org/10.3390/cancers18091471
Vancouver
Shpitzer D, Perry C, Shragai T, Melamed G, Smith MR, Vitkon R, et al. Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations. Cancers. 2026;18(9):1471. doi:10.3390/cancers18091471
BibTeX
@article{Shpitzer2026,
author = {Shpitzer, Dor and Perry, Chava and Shragai, Tamir and Melamed, Guy and Smith, Mitchell R and Vitkon, Roy and Alapi, Hillel and Avivi, Irit},
title = {Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations},
journal = {Cancers},
year = {2026},
volume = {18},
number = {9},
pages = {1471},
doi = {10.3390/cancers18091471}
}
EUVIMED